Literature DB >> 16794568

Mecamylamine attenuates cue-induced reinstatement of nicotine-seeking behavior in rats.

Xiu Liu1, Anthony R Caggiula, Susan K Yee, Hiroko Nobuta, Alan F Sved, Robert N Pechnick, Russell E Poland.   

Abstract

Mecamylamine, a noncompetitive nicotinic cholinergic antagonist, inhibits nicotine self-administration in animals and may attenuate tobacco smoking in humans trying to quit. Our preliminary data suggested that this agent, at a dose of 2 mg/kg (subcutaneous (s.c.)), also attenuates cue-induced relapse to nicotine-seeking behavior in rats. This study determined whether mecamylamine-induced attenuation can be obtained at doses lower than the high 2 mg/kg dose used in the first study, and whether it is specific to nicotine-associated cues. Male Sprague-Dawley rats were trained to intravenously self-administer nicotine (0.03 mg/kg/infusion) on a fixed-ratio 5 schedule. Each infusion was accompanied by a visual cue (1 s onset of a lever light followed by offset of a house light for 20 s during which time no infusions could be obtained). After the nicotine-maintained responding was extinguished by withholding the delivery of nicotine (saline substitution) and its associated cue, reinstatement tests were conducted. Response-contingent re-presentation of the cue without further availability of nicotine significantly reinstated extinguished responding at the previously nicotine-reinforced lever. Pretreatment with mecamylamine (0.5, 1, and 2 mg/kg, s.c.) dose-dependently attenuated the cue-induced reinstatement of lever responding. Mecamylamine did not change food-taking and -seeking responses, whereas the highest dose (2 mg/kg) decreased nicotine self-administration behavior. The results confirm previous findings that stimuli conditioned to nicotine self-administration effectively elicit reinstatement of nicotine-seeking behavior after extinction and demonstrate that mecamylamine, besides suppressing self-administration of nicotine, effectively attenuates cue-induced nicotine-seeking behavior. These findings suggest that the response-reinstatement procedures used in this study may be useful for studying neurobiological mechanisms of nicotine-seeking behavior and that mecamylamine-like drugs may be potential candidates for pharmacological treatment and prevention of relapse to tobacco smoking in abstinent smokers.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16794568      PMCID: PMC2811395          DOI: 10.1038/sj.npp.1301129

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  86 in total

1.  Responses to smoking-related stimuli and early relapse to smoking.

Authors:  R Niaura; D Abrams; B Demuth; R Pinto; P Monti
Journal:  Addict Behav       Date:  1989       Impact factor: 3.913

2.  Effects of mecamylamine on human cigarette smoking and subjective ratings.

Authors:  R Nemeth-Coslett; J E Henningfield; M K O'Keeffe; R R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

3.  Does watching others smoke increase smoking?

Authors:  C Surawy; R Stepney; T Cox
Journal:  Br J Addict       Date:  1985-06

4.  Persistent behavior at high rates maintained by intravenous self-administration of nicotine.

Authors:  S R Goldberg; R D Spealman; D M Goldberg
Journal:  Science       Date:  1981-10-30       Impact factor: 47.728

5.  Nitric oxide synthesis inhibition attenuates conditioned reinstatement of ethanol-seeking, but not the primary reinforcing effects of ethanol.

Authors:  Xiu Liu; Friedbert Weiss
Journal:  Alcohol Clin Exp Res       Date:  2004-08       Impact factor: 3.455

6.  Antagonism of the nicotine-induced changes of the striatal dopamine metabolism in mice by mecamylamine and pempidine.

Authors:  H Haikala; L Ahtee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-08       Impact factor: 3.000

7.  The acetylcholine receptor of the neuromuscular junction recognizes mecamylamine as a noncompetitive antagonist.

Authors:  W A Varanda; Y Aracava; S M Sherby; W G VanMeter; M E Eldefrawi; E X Albuquerque
Journal:  Mol Pharmacol       Date:  1985-08       Impact factor: 4.436

8.  Naltrexone attenuates cue- but not drug-induced methamphetamine seeking: a possible mechanism for the dissociation of primary and secondary reward.

Authors:  Kusnandar Anggadiredja; Katsuya Sakimura; Takato Hiranita; Tsuneyuki Yamamoto
Journal:  Brain Res       Date:  2004-09-24       Impact factor: 3.252

9.  Nicotine does not improve discrimination of brain stimulation reward by rats.

Authors:  P B Clarke; R Kumar
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

10.  Mecamylamine increases nicotine preference and attenuates nicotine discrimination.

Authors:  J E Rose; A Sampson; E D Levin; J E Henningfield
Journal:  Pharmacol Biochem Behav       Date:  1989-04       Impact factor: 3.533

View more
  38 in total

1.  Naltrexone attenuation of conditioned but not primary reinforcement of nicotine in rats.

Authors:  Xiu Liu; Matthew I Palmatier; Anthony R Caggiula; Alan F Sved; Eric C Donny; Maysa Gharib; Sheri Booth
Journal:  Psychopharmacology (Berl)       Date:  2008-09-21       Impact factor: 4.530

2.  The motivation to obtain nicotine-conditioned reinforcers depends on nicotine dose.

Authors:  M I Palmatier; S B Coddington; X Liu; E C Donny; A R Caggiula; A F Sved
Journal:  Neuropharmacology       Date:  2008-09-17       Impact factor: 5.250

3.  mGluR5 antagonism attenuates methamphetamine reinforcement and prevents reinstatement of methamphetamine-seeking behavior in rats.

Authors:  Justin T Gass; Megan P H Osborne; Noreen L Watson; Jordan L Brown; M Foster Olive
Journal:  Neuropsychopharmacology       Date:  2008-09-17       Impact factor: 7.853

Review 4.  Behavioral mechanisms underlying nicotine reinforcement.

Authors:  Laura E Rupprecht; Tracy T Smith; Rachel L Schassburger; Deanne M Buffalari; Alan F Sved; Eric C Donny
Journal:  Curr Top Behav Neurosci       Date:  2015

5.  The effects of response operandum and prior food training on intravenous nicotine self-administration in rats.

Authors:  Kelly J Clemens; Stephanie Caillé; Martine Cador
Journal:  Psychopharmacology (Berl)       Date:  2010-05-01       Impact factor: 4.530

Review 6.  [Pharmacotherapeutic treatment strategies for smoking cessation].

Authors:  N Vasic; R C Wolf; N Wolf; B J Connemann; Z Sosic-Vasic
Journal:  Nervenarzt       Date:  2011-11       Impact factor: 1.214

7.  The alpha4beta2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats.

Authors:  Eoin C O'Connor; Dale Parker; Hans Rollema; Andy N Mead
Journal:  Psychopharmacology (Berl)       Date:  2009-12-05       Impact factor: 4.530

Review 8.  Effects of nicotine in experimental animals and humans: an update on addictive properties.

Authors:  Bernard Le Foll; Steven R Goldberg
Journal:  Handb Exp Pharmacol       Date:  2009

Review 9.  The neuropharmacology of relapse to food seeking: methodology, main findings, and comparison with relapse to drug seeking.

Authors:  Sunila G Nair; Tristan Adams-Deutsch; David H Epstein; Yavin Shaham
Journal:  Prog Neurobiol       Date:  2009-06-02       Impact factor: 11.685

Review 10.  Role of the glutamatergic system in nicotine dependence : implications for the discovery and development of new pharmacological smoking cessation therapies.

Authors:  Matthias E Liechti; Athina Markou
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.